Highly active antiretroviral therapy and the cardiovascular system: The heart of the matter

被引:8
|
作者
Barbaro, G [1 ]
机构
[1] Univ Roma La Sapienza, Dept Med Pathophysiol, Rome, Italy
关键词
human immunodeficiency virus; acquired immunodeficiency syndrome; highly active antiretroviral therapy; cardiovascular disease;
D O I
10.1159/000073660
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Highly active antiretroviral therapy ( HAART) has prolonged many patients' lives, but many cardiac sequelae of HIV are not affected by HAART and continue to develop even with treatment. In addition, HAART itself causes in a high proportion of patients a metabolic syndrome, characterized by lipodystrophy/ lipoatrophy, dyslipidemia and insulin resistance that may be associated with an increase in coronary artery disease and stroke. Careful cardiovascular evaluation in the course of HIV disease can identify cardiac complications early enough to treat. All HIV-infected patients are candidates for antiretroviral therapy and patients already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk according to the available guidelines. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:177 / 179
页数:3
相关论文
共 50 条
  • [31] Reasons to switch highly active antiretroviral therapy
    Castelnuovo, F.
    Allegri, R.
    Bergamasco, A.
    El Hamad, I.
    Cristini, G.
    [J]. INFECTION, 2010, 38 : 46 - 46
  • [32] Daily dosing of highly active antiretroviral therapy
    Rosenbach, KA
    Allison, R
    Nadler, JP
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 686 - 692
  • [33] Gynecomastia associated with highly active antiretroviral therapy
    Manfredi, R
    Calza, L
    Chiodo, F
    [J]. ANNALS OF PHARMACOTHERAPY, 2001, 35 (04) : 438 - 439
  • [34] Cervical neoplasia and highly active antiretroviral therapy
    Xi, LF
    Kiviat, NB
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (14) : 1051 - 1053
  • [35] Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system
    Nath, Avindra
    Sacktor, Ned
    [J]. CURRENT OPINION IN NEUROLOGY, 2006, 19 (04) : 358 - 361
  • [36] Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection
    Plebani, A
    Esposito, S
    Pinzani, R
    Fesslova, V
    Bojanin, J
    Salice, P
    Rossi, M
    Principi, N
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (06) : 559 - 563
  • [37] Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy
    Grover, SA
    Coupal, L
    Gilmore, N
    Mukherjee, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (05): : 586 - 591
  • [38] Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists
    Berns, Jeffrey S.
    Kasbekar, Nishaminy
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (01): : 117 - 129
  • [39] Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
    Sabin, CA
    Smith, CJ
    Gumley, H
    Murphy, G
    Lampe, FC
    Phillips, AN
    Prinz, B
    Youle, M
    Johnson, MA
    [J]. AIDS, 2004, 18 (16) : 2145 - 2151
  • [40] Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy
    Barrón, Y
    Cole, SR
    Greenblatt, RM
    Cohen, MH
    Anastos, K
    DeHovitz, JA
    Delapenha, R
    Gange, SJ
    [J]. AIDS, 2004, 18 (11) : 1579 - 1584